Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
复制标题
DOI：
10.1016/j.jtho.2018.08.2036
复制
发表时间：
2018-11-01
影响因子：
20.4
通讯作者：
Malik, Shakun M.
中科院分区：
文献类型：
--
作者：
Tsao, Anne S.;Lindwasser, O. Wolf;Malik, Shakun M.
2017年3月28-29日，美国国家癌症研究所（NCI）胸部恶性肿瘤指导委员会、国际肺癌研究协会和间皮瘤应用研究基金会在马里兰州贝塞斯达召开了NCI-国际肺癌研究协会-间皮瘤应用研究基金会间皮瘤临床试验计划会议。会议的目标是将主要院士、临床医生、科学家和美国食品和药物管理局聚集在一起，重点关注针对已诊断出恶性胸膜间皮瘤患者的临床试验的开展。鉴于新癌症靶点的发现影响了恶性间皮瘤新药和免疫疗法的临床开发，本次会议的目的是就通过 NCI 国家临床试验网络进行的至少两到三项改变实践的多模式临床试验达成共识。皇冠版权所有 (C) 2018 由 Elsevier Inc. 出版。
On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network. Crown Copyright (C) 2018 Published by Elsevier Inc.